Although these purported mechanisms of myotube atrophy in ESLD require further exploration, interventions targeting myostatin and proteolytic pathway regulators may provide a promising approach to offset sarcopenia progression in chronic liver disease. The gene discussed is MSTN; the disease is chronic liver failure.